17 October 2019
EMA/CHMP/571247/2019
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Toujeo

insulin glargine

On 17 October 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Toujeo. The marketing authorisation holder for this medicinal product is Sanofi-Aventis Deutschland GmbH.

The CHMP adopted a change to the existing indication as follows:[2]

"Treatment of diabetes mellitus in adults**, adolescents and children from the age of 6 years**".

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in bold

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union